财务业绩 - 公司第四季度净销售额为2.732亿美元，同比增长7%[4] - 第四季度调整后EBITDA为3.34亿美元，同比增长3%[12] - 第四季度调整后净收入为1.67亿美元，同比增长10%[14] - 第四季度调整后每股摊薄收益为0.41美元，同比增长10%[15] - 全年净销售额为101.77亿美元，同比增长4%[15] - 全年调整后EBITDA为11.12亿美元，同比下降1%[15] - 全年调整后每股摊薄收益为1.19美元，同比下降1%[15] - 公司2024财年净销售额为10.177亿美元，同比增长4%[37] - 2024财年毛利为3.131亿美元，同比增长5%[37] - 2024财年销售、一般及管理费用为2.598亿美元，同比增加15%[37] - 2024财年营业利润为5330万美元，同比下降26%[37] - 2024财年净利润为240万美元，同比下降93%[37] - 2024财年调整后EBITDA为1.112亿美元，同比下降1%[26] - 2024财年调整后净利润为4840万美元，同比下降1%[28] - 2024财年调整后每股收益为1.19美元，同比下降1%[29] - 公司2023财年第四季度净收入为15.2百万美元，同比增长10%[42] - 2023财年全年调整后净收入为48.4百万美元，同比下降1%[42] - 2023财年全年调整后毛利率为31.5%，同比上升0.3个百分点[42] - 2023财年全年调整后销售、一般及管理费用率为23.1%，同比上升1个百分点[42] - 2023财年全年调整后税前利润率为6.5%，同比下降1个百分点[42] - 2023财年全年调整后净利率为4.8%，同比下降0.2个百分点[42] - 2023财年全年调整后有效税率为26.9%，同比下降6.1个百分点[42] - 公司2024财年第四季度调整后每股收益预计为0.41美元[42] - 公司2024财年全年调整后每股收益预计为1.19美元[42] - 公司2024财年全年调整后净收入预计为697.4百万美元，同比增长4%[42] 业务表现 - 动物保健业务净销售额增长8%，达到7.065亿美元[39] - 动物保健业务调整后EBITDA增长7%，达到1.456亿美元[39] - 疫苗业务净销售额增长21%，达到1.209亿美元[39] - 矿物营养业务净销售额持平，达到2.437亿美元[39] - 绩效产品业务净销售额下降10%，达到0.675亿美元[39] - 公司总体净销售额增长4%，达到10.177亿美元[39] - 公司总体调整后EBITDA下降1%，达到1.112亿美元[39] - 净利润下降93%，至240万美元[39] 未来展望 - 公司预计2025财年净销售额将达到104亿美元至109亿美元之间[1] - 公司预计2025财年调整后EBITDA将达到1.18亿美元至1.26亿美元之间[1] - 公司计划在未来几个月内完成对Zoetis MFA业务的收购[3] - 2025财年预计净销售额为10.4-10.9亿美元，同比增长5%[30] - 2025财年预计调整后EBITDA为1.18-1.26亿美元，同比增长10%[30] 其他 - 收购相关交易成本为640万美元[39] - 外汇损失为2390万美元[40]

业务概况 - 公司是一家全球领先的动物保健产品开发、制造和商业化公司[73] - 公司在家禽和猪类等最快增长的食用动物品种细分市场中占据重要地位[73] - 公司拥有多样化和互补的产品组合以及强大的品牌知名度[73] - 公司开发、制造和销售约280种产品线,包括抗菌素、抗球虫药、营养特殊产品和疫苗[21] - 公司的MFAs和其他产品主要包括抗菌素和抗球虫药,销售对象主要为家禽、猪、牛和奶牛等行业[24][30][31][32][33] - 公司的营养特殊产品通过应用研究和与客户的商业试验开发,用于提高动物免疫系统功能和消化健康[25] - 公司开发并销售约50种家禽疫苗,同时也开发、制造和销售猪、牛和水产养殖的自身疫苗[26][27] - 公司的矿物质营养业务为客户提供约380种配方和浓度的微量矿物质产品,主要销往北美市场[28] - 公司的特殊产品业务主要面向个人护理、工业化学品和化学催化剂行业[29] 财务数据 - 公司2024财年动物保健业务收入706百万美元,同比增长7%[11] - 公司2024财年矿物营养业务收入244百万美元,基本持平[11] - 公司2024财年美国地区收入585百万美元,占总收入57%[14] - 公司2024财年拉丁美洲和加拿大地区收入248百万美元,占总收入24%[14] - 公司2024财年动物保健业务调整后EBITDA为146百万美元,占总调整后EBITDA的86%[16] - 公司2024财年动物保健业务净可识别资产为684百万美元,占总净可识别资产的70%[18] - 公司2024财年矿物营养业务调整后EBITDA为16百万美元,占总调整后EBITDA的10%[16] - 公司2024财年矿物营养业务净可识别资产为67百万美元,占总净可识别资产的7%[18] - 公司2024财年绩效产品业务调整后EBITDA为8百万美元,占总调整后EBITDA的5%[16] - 公司2024财年绩效产品业务净可识别资产为51百万美元,占总净可识别资产的5%[18] 知识产权 - 公司拥有约300项专利或待批专利申请，但认为没有单一专利对业务至关重要[46] - 公司拥有或有权使用约3,400项商标注册或待批申请[47] - 公司的技术、品牌和其他知识产权是其业务的重要组成部分[47] 监管合规 - 公司的许多动物保健和矿物营养产品需要政府机构许可才能上市[48] - 公司建立了从产品概念到上市和维护的全程流程和专门资源,以保持对监管要求的合规性[48] - 公司产品需要获得FDA和USDA等美国政府机构的审批才能在美国市场销售[49][50][51][52] - 公司产品需要满足安全性、有效性和生产质量标准要求[49][50][52] - 公司部分产品涉及抗菌素使用问题,可能受到相关法规限制[52][53][54][55] - 公司产品在欧盟市场也需要获得欧洲药品管理局(EMA)的市场准入许可[56][57][58][59] - 公司产品在巴西市场需要获得农业部(MAPA)的审批[60] - 公司产品在其他国家市场也需要满足当地监管要求[61][62] 人力资源 - 公司拥有经验丰富的销售团队和技术支持人员,与客户建立了牢固的咨询关系[74] - 公司拥有经验丰富的管理团队,员工团队多样化且技能娴熟[75] - 公司认为员工是最宝贵的资产,采取多项措施吸引和留住人才[77][78][79][80] 生产和研发 - 公司自有生产设施和合同制造商相结合,满足生产需求[81] - 公司在多个国家和地区设有研发和产品测试设施,提供广泛的研发服务[82] - 公司遵守环境法规,采取措施确保运营合规[83] 风险因素 - 公司业务受食用动物疾病爆发的严重影响，可能导致大规模动物死亡或预防性屠杀，以及动物蛋白消费和需求下降[99] - 公司产品中含有维吉尼亚霉素、四环素和新霉素等被FDA列为医疗重要抗菌素的产品可能会受到使用限制[100] - 公司的Mecadox(卡巴多克)产品可能会被FDA撤销批准,这将对公司业务和财务状况产生重大不利影响[104] - 公司的医疗产品业务占净销售额约40%,这类产品的大幅销售下降会对公司业务产生重大不利影响[105] - 不利天气条件和自然灾害、COVID-19等疫情、气候变化可能会对公司的制造、物流和供应链以及客户产生负面影响[107][108][109,110,111] - 客户和分销商的持续整合、监管批准的风险、原材料成本波动、生产设施运营风险等可能对公司业务产生重大不利影响[113][122,123,125][126][127,128,130] - 公司在海外经营面临各种政治、经济和监管风险[132,133][138,140] - 公司部分员工受集体谈判协议的覆盖,可能会面临工厂停工或罢工的风险[141] - 公司的未来成功依赖于高级管理人员和关键人员的持续贡献,流失关键人才可能对业务造成重大不利影响[142] - 公司作为动物保健药品和疫苗生产商,需要进行动物试验,这可能受到争议和负面影响[143] - 公司面临环境和行业风险,如爆炸、

Phibro Animal Health (PAHC) shares soared 10.2% in the last trading session to close at $20.94. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 1% gain over the past four weeks. Phibro scored a strong price increase, on investors' optimism driven by its impending fiscal fourth-quarter 2024 financial results, which is slated to be released on Aug 28 post the closing bell. The Zacks Consensus Estimate for the fourth quarter revenue ...

The upcoming report from Phibro Animal Health (PAHC) is expected to reveal quarterly earnings of $0.34 per share, indicating a decline of 10.5% compared to the year-ago period. Analysts forecast revenues of $262.44 million, representing an increase of 2.9% year over year. Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe. Prior to a comp ...

Phibro Animal Health (PAHC) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended June 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price. The earnings report, which is expected to be released on August 28, 2024, might help the stock move higher if these key numbers are better ...

Phibro Animal Health (PAHC) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by ...

While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With this in mind, we are always looking at value, growth, and momentum trends to discover great companies.Looking at the history of these trends, perhaps none is more beloved than value investing. This strategy simply looks to identify companies that are being undervalued by the broader market. Value investors use a v ...

While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With this in mind, we are always looking at value, growth, and momentum trends to discover great companies.Looking at the history of these trends, perhaps none is more beloved than value investing. This strategy simply looks to identify companies that are being undervalued by the broader market. Value investors rely on ...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.Considering these trends, value investing is clearly one of the most preferred ways to find strong stocks in any type of market. Value investors use fundamental analysis and traditional valuation metrics to find stocks that they believe are being un ...

Have you looked into how Phibro Animal Health (PAHC) performed internationally during the quarter ending March 2024? Considering the widespread global presence of this maker of animal health products and nutritional supplements, examining the trends in international revenues is essential for assessing its financial resilience and prospects for growth.In today's increasingly interconnected global economy, a company's ability to tap into international markets can be a pivotal factor in shaping its overall fin ...